Pathological versus physiological left ventricular hypertrophy: a review
- PMID: 9531002
- DOI: 10.1080/026404198366849
Pathological versus physiological left ventricular hypertrophy: a review
Abstract
Left ventricular hypertrophy is recognized as an independent risk factor for cardiovascular morbid events. The primary mechanisms responsible for stimulating it are unknown. Epidemiological theories suggest that left ventricular hypertrophy is a continuous variable with no threshold, while morphological studies argue that it is the structure, or quality, and function of the myocardium (and therefore non-continuous), not the quantity of the myocardial mass, that poses the cardiovascular risk. Although left ventricular hypertrophy has been classically viewed as an adaptive response of the cardiovascular system to an imposed load, it has been demonstrated that haemodynamic overloading in selected hypertensive patients is not the sole determinant of left ventricular structure and function. Pathological and physiological states of left ventricular hypertrophy have been described primarily using criteria focusing on normal chamber performance and oxygen delivery as well as the reversibility of the hypertrophy once the overload is removed. Both states are also defined by the nature of the imposed load and the resulting myocardial adaptations. This review addresses the pathological and physiological states of left ventricular hypertrophy, the hypertrophy patterns, and the corresponding structural and functional characteristics, together with some of the biochemical factors thought to influence remodelling.
Similar articles
-
[Is secondary myocardial hypertrophy a physiological or pathological adaptive mechanism?].Z Kardiol. 1982 Aug;71(8):489-96. Z Kardiol. 1982. PMID: 6215776 Review. German.
-
Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy.J Hypertens. 2011 Jan;29(1):17-26. doi: 10.1097/HJH.0b013e328340d787. J Hypertens. 2011. PMID: 21045723 Review.
-
Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.J Hypertens Suppl. 1996 Dec;14(5):S43-9. J Hypertens Suppl. 1996. PMID: 9120684
-
[Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy].Rev Esp Cardiol. 2007 Jan;60(1):15-23. Rev Esp Cardiol. 2007. PMID: 17288951 Spanish.
-
[Ventricular hypertrophy as an expression of hypertensive damage].Cardiologia. 1991 Dec;36(12 Suppl 1):79-84. Cardiologia. 1991. PMID: 1841809 Review. Italian.
Cited by
-
Unique aspects of competitive weightlifting: performance, training and physiology.Sports Med. 2012 Sep 1;42(9):769-90. doi: 10.1007/BF03262294. Sports Med. 2012. PMID: 22873835 Review.
-
Short-term akt activation in cardiac muscle cells improves contractile function in failing hearts.Am J Pathol. 2012 Dec;181(6):1969-76. doi: 10.1016/j.ajpath.2012.08.020. Epub 2012 Sep 30. Am J Pathol. 2012. PMID: 23031259 Free PMC article.
-
Hold me tight: Role of the heat shock protein family of chaperones in cardiac disease.Circulation. 2010 Oct 26;122(17):1740-51. doi: 10.1161/CIRCULATIONAHA.110.942250. Circulation. 2010. PMID: 20975010 Free PMC article. Review. No abstract available.
-
Epigenome-wide DNA methylation profiling in comparison between pathological and physiological hypertrophy of human cardiomyocytes.Front Genet. 2023 Sep 27;14:1264382. doi: 10.3389/fgene.2023.1264382. eCollection 2023. Front Genet. 2023. PMID: 37829282 Free PMC article.
-
The prevalence of left ventricular hypertrophy associated with type-2 diabetes in Shiraz, Iran: a cross-sectional study.BMC Cardiovasc Disord. 2023 Feb 15;23(1):88. doi: 10.1186/s12872-023-03083-4. BMC Cardiovasc Disord. 2023. PMID: 36792995 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical